Eli Lilly and Co / LLY

Equity | Generated Sep 25, 2026 12:28 AM EDT

Current price	Daily move	Bid / Ask	Previous close
$1,184.10	+2.21 +0.19%	-/-	$1,181.89

Market	**NYSE**
Industry	**Pharmaceuticals**
Market data as of	**Sep 25, 2026 12:28 AM EDT**

JW Intelligence Report

Complete | 3 of 3 sections | Sep 24, 2026 7:51 PM EDT

JW Rank	Rank label	Confidence	IV percentile
69.8 / 100	Constructive	high	30 / 100

Model reference	Upside scenario	Risk reference	Wheel strategy fit
$1,168.00	$1,240.00	$1,138.00	64 / 100

Options stance	**bullish**
Tail-risk safety	**32 / 100**
JW Rank data coverage / as of	**100.0% | Sep 24, 2026 7:51 PM EDT**

Key insight

Lilly (LLY) Option Market Prices in Positive Sentiment After FDA Approval

Market read

The option market for LLY is pricing in a bullish outlook following the recent FDA approval of Onswik, a new once-weekly basal insulin. The stock price surged on the news, and implied volatility has increased, suggesting traders expect further price movement. While some analysts remain cautious about chasing the current rally, the overall sentiment is positive due to the potential for Onswik to become a significant revenue driver in the diabetes market.

Strategy context

The recent FDA approval of Onswik adds to the positive momentum surrounding LLY. The stock is currently trading near its 50-day moving average, suggesting potential for further upside.

JW AI conclusions

Short- and medium-term model interpretation

AI context bias	**Bullish**
AI analysis updated	**Sep 24, 2026 10:00 AM EDT**

Short-term scenario

Cautious dip-buy, not a chase. The Onswik approval is a real but secondary catalyst versus incretins; 1-3 week upside is plausible if the gap holds, but a news fade back toward the 50-day area is a credible alternative. Uncertainty is high. Not investment advice.

Three-month outlook

Moderately bullish base case with a wide range and elevated uncertainty. If tirzepatide growth, Foundayo commercialization, and the Oct 29 earnings print hold up, a path toward the Street cluster near $1,300-$1,330 is reasonable, with Onswik a supporting diabetes product rather than the main driver. A stronger tape could retest the $1,293 high and stretch toward the mid-$1,300s if competitive headlines cool. A weaker case is a retrace toward roughly $1,050-$1,120 on obesity-competition data (Novo, Roche, Viking and others), U.S. pricing or policy pressure, or multiple compression from a high-30s trailing P/E on a ~$1T pharma name. Retatrutide remains mostly a 2027 filing story, so near-term data flow can move sentiment without near-term revenue. These levels are scenarios, not forecasts, and can be wrong.

Market sentiment

Moderately bullish but not euphoric. Accounts are circulating the Onswik FDA nod as a convenience win in diabetes and a competitive response to Novo's weekly insulin. Active traders note LLY as one of the strongest names on the tape but already extended, with one setup preferring a pullback into roughly $1,162-$1,167 rather than chasing the open, and a near-term reference near the session high. Analyst PT maintenance and raises (Guggenheim, TD Cowen) are being reshared with a constructive incretin tone. A minority of posts still argue the market underestimates Novo and other obesity competitors. Overall X tone is franchise-positive and valuation-aware, with low conviction on chasing today's print.

Supporting evidence

LLY's stock price jumped $32.39 (+2.81%) on September 24th following FDA approval of Onswik. | Implied volatility has increased, indicating expectations for further price movement. | Analyst actions are mostly supportive, with several upgrades and target price increases. | The market is optimistic about LLY's future growth prospects driven by its incretin franchise.

Risk watch

LLY's valuation is elevated, with a trailing P/E ratio of around 39. | Competition in the diabetes and obesity markets remains intense.

Enhanced price structure

45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor

JW RANK FACTOR PROFILE	COVERAGE	0 — 50 — 100
Liquidity	100.0%	96.0
Strategy Fit	100.0%	63.7
Technical Trend	100.0%	79.6
Market Tail Risk	100.0%	32.0
Fundamental Quality	100.0%	84.2
Volatility Pressure	100.0%	59.5

Decision summary

Primary model reads before the detailed indicator appendix

Momentum	Institutional flow	Structure	Volatility
strong_bull	**Above MVWAP**	**Above 200D trend**	**medium**

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	**STRONG BULL | neutral | MACD accelerating**
Trend signal	**STRONG BULL**
RSI signal	**neutral**
RSI (7 / 14 / 21)	**65.57 / 55.30 / 52.98**
RSI velocity	**1.46**
MACD line / signal / histogram	**-5.46 / - / -10.26**
MACD acceleration	**1.95**
Stochastic K / D	**69.11 / 66.68**

Institutional footprints

Volume-weighted cost, price location and flow

Current read	**Above institutional MVWAP | Distribution bias**
Institutional flow	**-3.48**
20-day MVWAP	**$1,153.90**
Price vs 20-day MVWAP	**+2.62%**
Daily reference VWAP	**$1,176.89**
Price vs daily reference	**+0.61%**
Volume	**1.34M**

Structural context

Long-term trend and volatility boundaries

Current read	**Above 200-day trend | Negative macro velocity**
Macro velocity	**-2.78**
20-day / 200-day SMA	**$1,150.44 / $1,069.16**
Bollinger range	**$1,112.02 - $1,188.86**
Bollinger position	**0.909**

Options and volatility intelligence

Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
23 / 100	23 / 100	89.95	146.15

Market regime	**DANGER ZONE**
Tail-risk regime	**NORMAL TAIL RISK**
Term structure	**backwardation**
Term slope	**-2.65 pts**
Skew read	**balanced**
Liquidity / quote coverage	**100.0%**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Sep 24, 2026 2:53 PM EDT**
Options data quality	**Coverage 88.9%**

Option term structure

ATM implied-volatility curve by days to expiration



Downward-sloping ATM volatility term structure

EXPIRATION	DTE	ATM IV	STATE
2026-09-25	1	34.7%	-
2026-10-02	8	31.2%	-
2026-10-09	15	32.0%	-

Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

Bull Put Spread reference

Short $1,170.00 | Long $1,165.00 | Width $5.00 | Net credit $0.29



Max profit $29.00 | Max loss -$471.00 | Break-even $1,169.71 | Per contract at expiry

Bear Call Spread reference

Short $1,205.00 | Long $1,210.00 | Width $5.00 | Net credit $1.27



Max profit $127.00 | Max loss -$373.00 | Break-even $1,206.27 | Per contract at expiry

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	**2026-10-29**
Earnings IV-crush risk	**NOT MEASURED**
VIX	**15.54**
VVIX	**89.95**
SKEW index	**146.15**
Observation confidence	**high**
Option quote quality	**reliable**
Contracts observed	**135**

Event and tail-risk context (continued)

Known event windows and broad volatility conditions

FIELD	VALUE
Contracts with quotes	**135**

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The option market for LLY is pricing in a bullish outlook following the recent FDA approval of Onswik, a new once-weekly basal insulin. The stock price surged on the news, and implied volatility has increased, suggesting traders expect further price movement. While some analysts remain cautious about chasing the current rally, the overall sentiment is positive due to the potential for Onswik to become a significant revenue driver in the diabetes market.

Options context

Lilly (LLY) Option Market Prices in Positive Sentiment After FDA Approval

Wheel context

The recent FDA approval of Onswik adds to the positive momentum surrounding LLY. The stock is currently trading near its 50-day moving average, suggesting potential for further upside.

Observed evidence

LLY's stock price jumped $32.39 (+2.81%) on September 24th following FDA approval of Onswik. | Implied volatility has increased, indicating expectations for further price movement. | Analyst actions are mostly supportive, with several upgrades and target price increases. | The market is optimistic about LLY's future growth prospects driven by its incretin franchise.

Principal risks to monitor

LLY's valuation is elevated, with a trailing P/E ratio of around 39. | Competition in the diabetes and obesity markets remains intense.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization **$1.08T**	P/E (TTM) **41.27**
ROE **92.6%**	Revenue growth **31.7%**
EPS growth **49.3%**	Operating margin **42.2%**
Net profit margin **33.5%**	Gross margin **-**
Free cash flow CAGR **5.9%**	Debt / equity **1.60**
Dividend yield **0.8%**	Beta **0.43**
52-week range **$712.05 - $1,292.65**	

Company or fund profile

Issuer identity and classification

Name **Eli Lilly and Co**	Market **NYSE**
Industry **Pharmaceuticals**	Country **US**
Currency **USD**	IPO date **1970-07-09**
Shares outstanding **941.74M**	52-week return **55.0%**
Book value per share **$35.98**	Revenue per share **$89.14**

Website	**lilly.com**

Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal

Sep 24, 2026 11:15 AM EDT

Covered Call | 2026-09-25

At signal $1,192.43 | Current $1,184.10

SHORT **Option $1,170.00 B $23.95 / A $26.70**

High turnover | CR $25.33

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	**$32.75**
ATR as % of price	**2.8%**
Volatility environment	**medium**
Current IV	**32.7%**
IV rank	**27 / 100**
IV percentile	**30 / 100**
Technical Snapshot IV source	**Private fundamentals snapshot**
Technical Snapshot IV observed at	**Sep 24, 2026 3:50 PM EDT**

Technical health and risk radar

Derived indicator health and event context

Overall health	**82 / 100**
Trend health	**92 / 100**
Momentum health	**99 / 100**
Volatility health	**68 / 100**
Structure health	**59 / 100**
Earnings risk / date	**low | 2026-10-29**
Macro risk	**unknown**
Volatility risk	**medium**
Structure risk	**medium**

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	**$1,150.44 / $1,177.13 / $1,069.16**
EMA (9 / 21)	**$1,158.37 / $1,160.66**
Bollinger upper / middle / lower	**$1,188.86 / $1,150.44 / $1,112.02**

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	**0.909**
True high / low	**$1,197.79 / $1,150.99**
5-day true high / low	**$1,197.79 / $1,134.41**

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	-2.783	**-**
SMA50	0.080	**-**
MVWAP20	-3.482	**-**
MACD	1.948	**-**
RSI	1.459	**-**
Volume	145335.330	**-**
ATR	0.916	**-**
T1	-	**-8.39 / 1156.48 / 1188.88 / 1145.98**
T2	-	**-8.87 / 1161.21 / 1180.53 / 1139.26**
T3	-	**-11.30 / 1164.34 / 1170.90 / 1134.41**

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	**$1,188.55**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Sep 24, 2026 2:53 PM EDT**
Options data coverage	**88.9%**
SKEW regime	**HIGH TAIL RISK SKEW**
VVIX regime	**VVIX FLAT**
Front expiration / DTE	**2026-09-25 | 1 DTE**
Front at-the-money IV	**34.7%**
25-delta skew	**-1.71**
Put / Call 25-delta	**$1,170.00 / $1,205.00 Delta 0.239**
Median option bid/ask spread	**21.0%**
Bid/ask spread	**-**
Contracts observed / quoted	**135 / 135**

Price context

Last Price: 1,188.55 | Bid: 1,188.24 | Ask: 1,188.88 | Previous Close: 1,150.99 | Change: 37.56 | Daily change: 3.26% | Update Time: 2026-09-24T14:53:16.846324-04:00 | Latest History Date: 2026-09-24 | Latest History Price: 1,188.55

Historical context

Trading-day sample: 60 sessions | First Date: 2026-07-01 | Latest Date: 2026-09-24 | Latest Price: 1,188.55 | Max Drawdown 60d Percent: -12.86%

Fundamental context

Current Iv Percent: 31.94% | Iv Rank: 22.91 | Iv Percentile: 23.11 | Next Earnings Date: 2026-10-29 | Ex Dividend Date: 2026-08-13

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	**jasonwheel.com**
Terms of Use	**jasonwheel.com / Terms**
Privacy Policy	**jasonwheel.com / Privacy**
Options Disclosure Document	**theocc.com / Options Disclosure Document**